Drug Search Results
More Filters [+]

Albiglutide

Alternative Names: albiglutide, gsk716155, tanzeum
Latest Update: 2023-09-12
Latest Update Note: News Article

Product Description

Albiglutide (Tanzeum) is a glucagon-like peptide 1 (GLP-1) receptor agonist labeled as an adjunct to diet and exercise for the management of type 2 diabetes mellitus in adults. As with other GLP-1 receptor agonists, albiglutide stimulates postmeal insulin secretion and slows gastric emptying to promote satiety (Sourced from: https://www.aafp.org/afp/2017/0415/p521.html)

Mechanisms of Action: GLP-1 Agonist

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Brazil | Canada | European Medicines Agency | Hungary | Ireland | Italy | Lithuania | Portugal | Spain | Sweden | United Kingdom

Approved Indications: Pancreatitis | Type 1 Diabetes | Acidosis | Diabetic Ketoacidosis | General Diabetes | Type 2 Diabetes

Known Adverse Events: Back Pain | Pain Unspecified | Respiratory Tract Infections | Arthralgia | Sinusitis | Diarrhea | Influenza, Human

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Albiglutide

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Type 2 Diabetes|Motion Sickness

Phase 3: Type 2 Diabetes|Kidney Diseases|Respiratory Distress Syndrome, Newborn

Phase 2: Type 2 Diabetes|Heart Failure|Type 1 Diabetes

Phase 1: Type 2 Diabetes

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CER-4-T2D

N/A

Active, not recruiting

Kidney Diseases|Type 2 Diabetes

2024-07-31

NCT03015519

P3

Withdrawn

Type 2 Diabetes

2020-04-20

Harmony Outcomes

P4

Completed

Type 2 Diabetes

2020-01-29

RDMSTEP

N/A

Completed

Type 2 Diabetes

2018-12-01

Recent News Events